TY - JOUR
T1 - Decreasing treatment burden in HPV-related OPSCC
T2 - A systematic review of clinical trials
AU - Iorio, Giuseppe Carlo
AU - Arcadipane, Francesca
AU - Martini, Stefania
AU - Ricardi, Umberto
AU - Franco, Pierfrancesco
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/4
Y1 - 2021/4
N2 - Introduction: Favorable outcomes are observed after treatment with standard chemoradiotherapy (CRT) for Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) patients. The consistent growing interest on treatment-related toxicity burden, potentially jeopardizing survivors’ quality of life, led clinicians to investigate possible de-escalation strategies. Materials and Methods: A comprehensive systematic literature search of clinical trials was performed through the EMBASE database to provide an overview of the de-escalation strategies spectrum. Additionally, hand searching and clinicaltrials.gov were also used. Results: Herein, we report and discuss different approaches to de-escalation of therapy, with respect to both local and systemic strategies. Conclusions: Several promising de-escalation experiences have been published. However, while further evidence is awaited, no changes in the management nor deviation from the standard of care should be made outside of clinical trials.
AB - Introduction: Favorable outcomes are observed after treatment with standard chemoradiotherapy (CRT) for Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) patients. The consistent growing interest on treatment-related toxicity burden, potentially jeopardizing survivors’ quality of life, led clinicians to investigate possible de-escalation strategies. Materials and Methods: A comprehensive systematic literature search of clinical trials was performed through the EMBASE database to provide an overview of the de-escalation strategies spectrum. Additionally, hand searching and clinicaltrials.gov were also used. Results: Herein, we report and discuss different approaches to de-escalation of therapy, with respect to both local and systemic strategies. Conclusions: Several promising de-escalation experiences have been published. However, while further evidence is awaited, no changes in the management nor deviation from the standard of care should be made outside of clinical trials.
KW - Cetuximab
KW - Cisplatin
KW - De-escalation
KW - De-intensification
KW - HPV
KW - Oropharynx cancer
KW - Radiotherapy
KW - TORS
UR - http://www.scopus.com/inward/record.url?scp=85102436525&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2021.103243
DO - 10.1016/j.critrevonc.2021.103243
M3 - Review article
SN - 1040-8428
VL - 160
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103243
ER -